

July 1, 1990



Cancer Research

VOLUME 50 • NO. 13 • PP 3811-4176
ISSN 0008-5472 • CNREA 8



UNIVERSITY OF HAWAII, CANCER RESEARCH CENTER OF HAWAII TWO TENURE TRACK POSITIONS FOR RESEARCH MEDICAL ONCOLOGISTS

The University of Hawaii Cancer Research Center of Hawaii is seeking applications from medical oncologists for two tenure track faculty positions in the Center's Clinical Research-Cancer Control Program.

The Center conducts clinical cancer research and cancer control research for participation by all cancer health care professionals in Hawaii. The Center maintains full membership in SWOG and NSABP and a satellite relationship with POG. In addition, local studies are developed to build on programmatic strengths in areas such as liver cancer, gastric cancer, natural products, and biologics. Cancer control research is focused on special underserved groups in Hawaii's multiethnic and multicultural population. The Center is responsible for providing educational, administrative and scientific support for all studies introduced into the community. Integrating laboratory research conducted at the Center into clinical studies is an essential activity. Faculty provide scientific direction to the program and generate national cooperative group and local study protocols.

It is anticipated that the successful candidate will also hold a teaching appointment in the Division of Oncology, Department of Medicine, John A. Burns School of Medicine and participate in a teaching-research oncology practice focused on special populations.

PROGRAM DIRECTOR

Applicants should have a record of accomplishment in clinical cancer research and teaching. They should have demonstrated organizational and administrative abilities and good communication skills.

Minimal requirements include an M.D. degree, board certification or equivalent in medical oncology and at least seven years of relevant experience. Rank and salary will be commensurate with experience.

RESEARCH MEDICAL ONCOLOGIST

Applicants should have experience in conducting clinical research studies and demonstrated teaching abilities. Applicants should also have laboratory research experience in pharmacology or cellular and molecular biology. Alternatively an active involvement in epidemiology or prevention and control research would also be encouraged. Minimum requirements include an M.D. degree, board certification or equivalent in medical oncology and at least three years of relevant experience. Rank and salary will be commensurate with experience. Interested applicants for the above positions should send a curriculum vitae and a list of three persons from whom references can be obtained to: Brian F. Issell, M.D., Director, Cancer Research Center of Hawaii, 1236 Lauhala Street, Honolulu, HI 96813. Closing Date: August 31, 1990 or until positions are filled.

The Lake Tahoe Symposium: Advances in Recombinant DNA Technology *October 15-17, 1990*

MOLECULAR GENETICS OF CANCER

Hyatt Regency Lake Tahoe Hotel
Incline Village, NV USA

- Pharmacia LKB Keynote Lecture* - Arthur B. Pardee (Dana-Farber Institute, Harvard, Boston)
- Session I - *Molecular Nature of Metastasis* - Victor Ling (Princess Margaret Hosp., Toronto)
- Session II - *Control of Cell Proliferation Through Molecular Manipulation of the Cell Cycle* - Enrique Rozengurt (Imperial Cancer Research Fund, London)
- Session III - *Cancer Risk Assessment Through Genetic Analysis* - Garrett Brodeur (Washington University School of Medicine, St. Louis)
- Interactive Practicum- *Innovations in Cancer Karyotyping* - Arthur Brothman (Eastern Virginia Medical School, Norfolk)
- Clinical Biotechnology Lecture* - Donald S. Coffey (The Johns Hopkins Medical School, Baltimore)
- Session IV - *Multifactorial Elements in the Genesis of Cancer* - Timothy Bowden (University of Arizona Medical School, Tucson)
- Session V - *Identification and Characterization of Suppressor Oncogenes* - Ruth Sager (Dana-Farber Institute, Harvard, Boston)

Each session will consist of three or four presentations. This, complemented with posters, discussions, and exhibits set at idyllic Lake Tahoe North Shore provides for a unique gathering. Registration: \$300, before 9/1/90; \$350, after 9/1/90. Contact: Symposium Coordinator, CATCMB, The Catholic University of America, 620 Michigan Ave., NE Washington, D.C. 20064. Tel. (202) 319-6161; FAX: (202) 319-5721.

COVER LEGEND



The cover features Professor Arnold Graffi, M.D., a distinguished and versatile cancer researcher, on the occasion of his eightieth birthday on June 19, 1990. Also recognized is the Cancer Institute in Berlin-Buch founded by Professor Graffi in 1948. Professor Graffi has dedicated his career to diverse aspects of cancer research. He was a pioneer in research on the mode of action of chemical carcinogens [Arch. Geschwulstforsch., 22: 2305–2312, 1963; 28: 81–88, 89–102, 234–248, 1963; Nature (Lond.), 214: 611, 1967; Chem.-Biol. Interact., 4: 81–89, 1972] and contributed to research on the phenomenon of cocarcinogenesis. He con-

ceived of mitochondria as cellular targets of carcinogens (Deut. Gesundheitsw., 22: 2305–2312, 1967; Biochem. Biophys. Res. Commun., 9: 418–423, 1965), derived probably from his early association with Otto Warburg. With his background in carcinogenesis, Graffi turned to viral oncology. He isolated one of the first mammalian retroviruses, that of myeloid leukemia in mice, commonly known as the Graffi virus (Arch. Geschwulstforsch., 20: 22–29, 1962; Z. Krebsforsch., 65: 384–395, 1963; Acta Biol. Med. Ger., 10: 63–78, 1963; Handb. Allg. Pathol., 6: 155–242, 1975). He also identified a polyoma type virus in the hamster (Arch. Geschwulstforsch., 20: 103–124, 1963; Acta Biol. Med. Ger., 12: 219–221) and a type D retrovirus in human cells (Proc. Natl. Acad. Sci. USA, 1172–1175, 1969; Arch. Geschwulstforsch., 45: 628–633, 1975; 46: 187–196, 1976; Intervirology, 4: 201–206, 1974). He contributed to the employment of prodrugs in cancer chemotherapy, based on the development of drug complexes as transport forms, which, upon reaching neoplastic cells, would be attached by enzymes to liberate the active drug (Cancer Treat. Rep., 61: 89–93, 1977; Pharmazie, 32: 465–467, 1977; 33: 358–361, 1978).

The Cancer Institute in Berlin-Buch is recognized internationally for its many contributions in diverse fields of cancer research. It also houses the editorial offices of the *Archiv für Geschwulstforschung*, a world-class cancer journal.

We are much indebted to Professor Dr. Volker Wunderlich, of the Berlin-Buch Institute, for information and photographs.

John H. Weisburger